Edgewise Therapeutics (EWTX) Competitors

$18.11
-0.07 (-0.39%)
(As of 05/17/2024 ET)

EWTX vs. GPCR, KURA, SUPN, TARO, SYRE, SDGR, RCUS, HRMY, LGND, and PTGX

Should you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Structure Therapeutics (GPCR), Kura Oncology (KURA), Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Spyre Therapeutics (SYRE), Schrödinger (SDGR), Arcus Biosciences (RCUS), Harmony Biosciences (HRMY), Ligand Pharmaceuticals (LGND), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical preparations" industry.

Edgewise Therapeutics vs.

Structure Therapeutics (NASDAQ:GPCR) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.

91.8% of Structure Therapeutics shares are owned by institutional investors. 32.0% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Structure Therapeutics presently has a consensus target price of $85.71, indicating a potential upside of 137.11%. Edgewise Therapeutics has a consensus target price of $31.20, indicating a potential upside of 72.28%. Given Edgewise Therapeutics' higher possible upside, equities analysts plainly believe Structure Therapeutics is more favorable than Edgewise Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Structure Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Edgewise Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Structure Therapeutics and Structure Therapeutics both had 4 articles in the media. Edgewise Therapeutics' average media sentiment score of 0.68 beat Structure Therapeutics' score of 0.63 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Structure Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Edgewise Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Edgewise Therapeutics received 5 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 78.95% of users gave Structure Therapeutics an outperform vote while only 62.50% of users gave Edgewise Therapeutics an outperform vote.

CompanyUnderperformOutperform
Structure TherapeuticsOutperform Votes
15
78.95%
Underperform Votes
4
21.05%
Edgewise TherapeuticsOutperform Votes
20
62.50%
Underperform Votes
12
37.50%

Structure Therapeutics is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Structure TherapeuticsN/AN/A-$89.62M-$0.77-46.95
Edgewise TherapeuticsN/AN/A-$100.16M-$1.55-11.68

Structure Therapeutics' return on equity of -29.09% beat Edgewise Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Structure TherapeuticsN/A -30.28% -28.21%
Edgewise Therapeutics N/A -29.09%-27.57%

Summary

Structure Therapeutics beats Edgewise Therapeutics on 7 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EWTX vs. The Competition

MetricEdgewise TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.70B$6.78B$5.17B$7.97B
Dividend YieldN/A2.72%43.86%3.91%
P/E Ratio-11.688.76111.5814.17
Price / SalesN/A259.572,362.1377.54
Price / CashN/A35.8536.3731.98
Price / Book3.165.795.744.77
Net Income-$100.16M$139.08M$105.38M$217.01M
7 Day Performance-1.20%1.49%1.85%2.90%
1 Month Performance17.22%3.77%4.73%6.58%
1 Year Performance94.52%-1.86%7.74%10.15%

Edgewise Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GPCR
Structure Therapeutics
1.6873 of 5 stars
$35.70
-0.8%
$85.71
+140.1%
+55.7%$1.66BN/A-46.3693
KURA
Kura Oncology
2.6951 of 5 stars
$20.91
+1.5%
$28.28
+35.2%
+78.5%$1.59BN/A-9.64142Analyst Forecast
SUPN
Supernus Pharmaceuticals
3.7673 of 5 stars
$28.97
-2.4%
$41.00
+41.5%
-17.3%$1.59B$607.52M-99.90652
TARO
Taro Pharmaceutical Industries
0.9739 of 5 stars
$42.33
+0.3%
$43.00
+1.6%
+46.9%$1.59B$572.95M34.701,554Upcoming Earnings
SYRE
Spyre Therapeutics
0.6186 of 5 stars
$39.29
+6.2%
$43.17
+9.9%
N/A$1.58B$890,000.00-0.5530Earnings Report
SDGR
Schrödinger
2.3511 of 5 stars
$23.25
+0.3%
$42.80
+84.1%
-19.7%$1.68B$188.48M-12.37867News Coverage
RCUS
Arcus Biosciences
1.2261 of 5 stars
$17.10
-0.6%
$41.25
+141.2%
-7.1%$1.57B$237M-5.50577Gap Up
HRMY
Harmony Biosciences
4.0783 of 5 stars
$29.86
-1.2%
$40.63
+36.1%
-18.3%$1.70B$582.02M12.93246Positive News
LGND
Ligand Pharmaceuticals
4.9086 of 5 stars
$85.29
+1.5%
$116.33
+36.4%
+9.0%$1.54B$131.31M16.5058Insider Selling
News Coverage
PTGX
Protagonist Therapeutics
1.2039 of 5 stars
$29.61
+1.0%
$38.00
+28.3%
+16.7%$1.74B$314.95M12.14112

Related Companies and Tools

This page (NASDAQ:EWTX) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners